Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 12/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20600991 | 1.00 | CCR1 (0.46) | CCR1KDM4EALDH1A1SMN1; SMN2IDO1 | |
| SCHEMBL20600915 | 0.90 | IDO1 (0.47) | CCR1KDM4EALDH1A1SMN1; SMN2IDO1 | |
| SCHEMBL20601141 | 0.85 | IDO1 (0.50) | CCR1KDM4EALDH1A1SMN1; SMN2IDO1 | |
| SCHEMBL20600950 | 0.85 | IDO1 (0.49) | CCR1KDM4EALDH1A1SMN1; SMN2IDO1 | |
| SCHEMBL20601136 | 0.85 | IDO1 (0.49) | CCR1KDM4EALDH1A1SMN1; SMN2IDO1 | |
| SCHEMBL28350995 | 0.84 | CCR1 (0.54) | CCR1KDM4EALDH1A1SMN1; SMN2IDO1 | |
| SCHEMBL20601082 | 0.84 | IDO1 (0.47) | CCR1IDO1CYP3A4CYP2D6 | |
| SCHEMBL20601013 | 0.83 | CCR1 (0.56) | CCR1KDM4EALDH1A1SMN1; SMN2IDO1 | |
| SCHEMBL20601011 | 0.83 | CCR1 (0.56) | CCR1KDM4EALDH1A1SMN1; SMN2IDO1 | |
| SCHEMBL20601070 | 0.83 | CCR1 (0.56) | CCR1KDM4EALDH1A1SMN1; SMN2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927078-B2 | Modulators of indoleamine 2,3-dioxygenase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| US-10927078-B2 | Modulators of indoleamine 2,3-dioxygenase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| US-20200165201-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-20200165201-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| EP-3645520-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019003141-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019003141-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165201-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH1 | CCR1 1565/4885KDM4E 657/4885ALDH1A1 816/4885 |
| US-10927078-B2 | Modulators of indoleamine 2,3-dioxygenase | IDO1, IDO2, TPH1 | CCR1 1565/4885KDM4E 657/4885ALDH1A1 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.